Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

Phase 1 Terminated 3 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

LOP628 is an antibody-drug conjugate (ADC) consisting of an anti-cKit humanized IgG1/κ antibody conjugated to a maytansine payload via a non-cleavable linker. LOP628 provides an opportunity to target cKit overexpressing tumors.

Timeline

Start: 2014-12
Primary completion: 2015-03
Completion: 2015-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LOP628	Unknown	—	Intravenous

Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

Summary

Timeline

Drugs

Indications